Experimental p38 mapk inhibitors for the treatment of urological cancers: observations from early clinical trials

Key Points

• The aim is to explore the effectiveness and safety of p38 MAPK inhibitors in treating urological cancers.
• Conducted early clinical trials focusing on p38 MAPK inhibitors.
• Evaluated the effectiveness and safety profiles of specific compounds.
• Collected and analyzed molecular data related to urological malignancies.
• Insufficient literature on the effectiveness of p38 MAPK inhibitors was identified.
• Safety profiles of the compounds require more comprehensive evaluation.
• Findings support the necessity of additional trials for conclusive results.